Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) and NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
Volatility & Risk
Treace Medical Concepts has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
Valuation & Earnings
This table compares Treace Medical Concepts and NeuroOne Medical Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Treace Medical Concepts | $212.69 million | 1.23 | -$59.00 million | ($0.93) | -4.33 |
| NeuroOne Medical Technologies | $12.10 million | 0.66 | -$3.61 million | ($0.95) | -0.93 |
NeuroOne Medical Technologies has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent recommendations for Treace Medical Concepts and NeuroOne Medical Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Treace Medical Concepts | 1 | 2 | 1 | 0 | 2.00 |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
Treace Medical Concepts presently has a consensus price target of $5.00, indicating a potential upside of 24.07%. NeuroOne Medical Technologies has a consensus price target of $7.33, indicating a potential upside of 734.28%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Treace Medical Concepts.
Profitability
This table compares Treace Medical Concepts and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Treace Medical Concepts | -28.99% | -71.37% | -30.49% |
| NeuroOne Medical Technologies | -71.50% | -128.12% | -86.34% |
Summary
Treace Medical Concepts beats NeuroOne Medical Technologies on 9 of the 14 factors compared between the two stocks.
About Treace Medical Concepts
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.
